Story perspectives

Moderna's mCombriax: Potential Dual Vaccine for COVID-19 and Flu

2/28/2026

Summary

Story summary

The European Medicines Agency (EMA) recommended approving Moderna's mCombriax for people aged 50 and older, potentially making it the first single-shot vaccine protecting against both COVID-19 and flu, pending Commission ratification.
In the United States, the U.S. Food and Drug Administration (FDA) initially declined to review the vaccine, a decision later reversed.
Moderna aims to offer mCombriax in Europe for the 2026-2027 season, amid declining demand for COVID vaccines.

1 of 1

Story summary

The European Medicines Agency (EMA) recommended approving Moderna's mCombriax for people aged 50 and older, potentially making it the first single-shot vaccine protecting against both COVID-19 and flu, pending Commission ratification.
In the United States, the U.S. Food and Drug Administration (FDA) initially declined to review the vaccine, a decision later reversed.
Moderna aims to offer mCombriax in Europe for the 2026-2027 season, amid declining demand for COVID vaccines.